Form 4: Accolade Inc. Director Jeffrey S. Brodsky Reports Acquisition of Restricted Stock Units

Director Jeffrey S. Brodsky reports acquisition of 8,715 Restricted Stock Units (RSUs) in Accolade, Inc. on March 1, 2024, vesting quarterly over one year.

Summary

• On March 1, 2024, Jeffrey S. Brodsky, a director of Accolade, Inc., acquired 8,715 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Accolade's Common Stock.
• The RSUs vest at a rate of 25% each quarter, starting from March 1, 2024, provided continuous service is maintained.
• Full vesting will occur on the one-year anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns director interests with company performance.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest over a one-year period contingent on continuous service, aligning the director's interests with the company's long-term performance.

Industry Context

This is a standard practice for aligning executive compensation with company performance in the healthcare technology industry.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a common practice among publicly traded companies to incentivize and align their interests with shareholders.
• Companies like Teladoc Health and Livongo (prior to its acquisition by Teladoc) have used similar equity-based compensation strategies for their executives and directors.
• The vesting schedule of one year is fairly standard, although some companies may use longer vesting periods to further incentivize long-term commitment.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term success.

Key Dates